(Total Views: 651)
Posted On: 01/12/2020 12:48:32 AM
Post# of 153887
Re: tconway1118 #14822
This study presented by you in this article , are very interesting , but I believe that they not comparable with our patients on Leronlimab,
They using mice with CCR5 deficiency ,
Leronlimab is attached to CCR5 the way it dose not affect normal immune responses of CCR5..
and this is collossal difference...IMO.
In addition CCR5 inhibitors may play positive effect against some bacteria , like Strep , Staph , etc
So possibly there is less chance that patients who do develop flu , will develop some secondary bacterial pneumonia which sometime is lethal..
This is my understanding.
All IMO as always.
They using mice with CCR5 deficiency ,
Leronlimab is attached to CCR5 the way it dose not affect normal immune responses of CCR5..
and this is collossal difference...IMO.
In addition CCR5 inhibitors may play positive effect against some bacteria , like Strep , Staph , etc
So possibly there is less chance that patients who do develop flu , will develop some secondary bacterial pneumonia which sometime is lethal..
This is my understanding.
All IMO as always.
(3)
(0)
